Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Health care stocks were flat to higher premarket Friday with the Shares Biotechnology ETF inactive and the Health Care Select Sector SPDR Fund recently up 0.3%.
Emergent Biosolutions shares rose nearly 18% after it said the US Food and Drug Administration has approved its supplemental application for ACAM2000, single-dose vaccine for smallpox and mpox.
NuCana shares tumbled by nearly 50% after it said it will discontinue phase 2 testing of its NUC-3373 drug candidate for the potential colorectal cancer treatment after determining that a combination of NUC-3373 with three different chemotherapies would unlikely meet the primary endpoint of superior progression-free survival compared with a control arm.
Ekso Bionics Holdings shares fell by over 13% after it priced a public offering of 6 million units and pre-funded units at $1 and $0.999, respectively, for gross proceeds of about $6 million.
US equity futures posted gains ahead of Friday's opening bell as traders digested the Federal Reserve's preferred measure of inflation.
The Dow Jones Industrial Average futures increased 0.3%, S&P 500 futures rose 0.5%, and Nasdaq futures were up 0.8%.
Oil prices were little changed, with front-month global benchmark North Sea Brent crude up 0.1% at $78.86 per barrel and US West Texas Intermediate crude was nearly flat at $75.92 per barrel.
Personal income, released at 8:30 am ET, gained 0.3% in July versus estimates compiled by Bloomberg for a 0.2% increase to match June's increase. The core personal consumption expenditures price index, the Fed's preferred inflation metric, increased 0.2% during the month, in line with estimates and matching June's uptick.
The Chicago Purchasing Managers' Index, due at 9:45 am ET, is expected to drop to 45.0 in August from July's 45.3.
No change is expected for Consumer sentiment, slated for 10 am ET, from the mid-month flash at 67.8 in the final reading for August.
In other world markets, Japan's Nikkei closed 0.7% higher, Hong Kong's Hang Seng ended 1.1% higher, and China's Shanghai Composite finished 0.7% higher. Meanwhile, the UK's FTSE 100 was up 0.3%, and Germany's DAX index also gained 0.3% in Europe's early afternoon session.
In equities, shares of Intuitive Machines were up 19% after the company secured a $116.9 million contract from the National Aeronautics and Space Administration. MongoDB (MDB) shares were 17% higher after the company posted higher fiscal Q2 revenue and raised its fiscal 2025 outlook.
On the losing side, NuCana shares were down 50% after the company discontinued its phase 2 trial of a prospective treatment for colorectal cancer. Elastic shares were 27% lower as analyst downgrades followed the company's recently issued fiscal 2025 revenue guidance that trailed Capital IQ analysts' estimates.
Thursday, NuCana plc announced that the NuTide:323 study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee.
While there were prognostic imbalances favoring the control arm, the Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan, and bevacizumab (NUFIRI+bev) was unlikely to achieve the study’s primary objective of superior Progression-Free Survival compared to the control arm of 5-FU, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bev) in the final analysis.
NuTide:323 is a Phase 2 study comparing NUC-3373/NUFIRI-bev to FOLFIRI-bev for unresectable metastatic colorectal cancer.
In all three arms, the treatment regimens were observed to have a favorable safety profile and to be generally well tolerated, with only 12 of the 175 patients (four patients in each arm) discontinuing treatment due to adverse events.
Mr. Griffith continued: “The results of the NuTide:323 study do not impact the ongoing NuTide:303 study, in which NUC-3373 is being combined with either pembrolizumab in solid tumors or docetaxel in patients with lung cancer. Furthermore, we are excited about the potential of NUC-7738, a novel agent that profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. We look forward to sharing the latest data from the Phase 2 part of the NuTide:701 study of NUC-7738 in combination with pembrolizumab in patients with melanoma at the ESMO annual conference in September 2024.”
William Blair has downgraded the stock to Market Perform, saying, “Given this was the first controlled trial with NUC-3373, we believe it will be difficult to regain investor interest in the program in other ongoing studies.”
As of June 30, 2024, NuCana had cash and cash equivalents of $15.3 million (11.6 million pounds), which is expected to provide a cash runway into the first quarter of 2025.
Price Action: At last check on Friday, NCNA stock was down 52.3% to $3.69 during the premarket session.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.